Newron advances Evenamide trials despite 2025 financial setbacks and secures €38M funding

Biopharmaceutical company Newron has pushed forward with its key drug, Evenamide, as part of a major Phase III programme. The company also secured fresh funding in early 2026, despite reporting a financial loss for the previous year. Multiple trials are now underway across different regions, with results anticipated by late 2026. Newron's Phase III ENIGMA-TRS programme for Evenamide began in mid-2025. The first trial, ENIGMA-TRS 1, launched in August 2025, with initial findings due in the fourth quarter of 2026. A second trial, ENIGMA-TRS 2, started in the U.S. in December 2025. Meanwhile, partner EA Pharma kicked off its own Phase III study in Japan in January 2026.

Financially, Newron faced challenges in 2025. The company posted a net loss of €13.2 million, a sharp turnaround from a €15.8 million profit in 2024. Licensing revenue also dropped significantly, from €51.4 million in 2024 to €19.1 million in 2025. Despite this, research spending remained high, with €15.1 million invested in development during the year. To strengthen its position, Newron raised up to €38 million in February 2026 through a capital increase. The funding came from both existing and new shareholders in Europe and Asia. This boosted liquidity, which stood at €28.9 million at the end of 2025, and extended financial support for the Phase III programme until 2027. Additionally, the European Investment Bank prolonged its financing agreements with the company through June 2028. As of March 22, 2026, Newron had 627.30 million shares outstanding. However, its stock traded around 45% below its yearly peak of €32.95.

The additional funding secures Newron's ability to continue Evenamide's Phase III trials until at least 2027. With trials progressing in the U.S. and Japan, the company expects key data by the end of 2026. Extended financing from the EIB further supports its long-term plans.